Signet Financial Management LLC Trims Stock Holdings in Fresenius Medical Care AG (NYSE:FMS)

Signet Financial Management LLC trimmed its position in shares of Fresenius Medical Care AG (NYSE:FMS) by 10.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,617 shares of the company’s stock after selling 3,595 shares during the period. Signet Financial Management LLC’s holdings in Fresenius Medical Care were worth $716,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Wulff Hansen & CO. boosted its holdings in Fresenius Medical Care by 1,809.0% in the second quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after purchasing an additional 325,439 shares in the last quarter. Moran Wealth Management LLC grew its stake in shares of Fresenius Medical Care by 47.0% during the 3rd quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock worth $4,971,000 after purchasing an additional 74,621 shares during the period. Quantinno Capital Management LP lifted its position in shares of Fresenius Medical Care by 78.9% during the 3rd quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock valued at $2,345,000 after acquiring an additional 48,554 shares during the period. Crossmark Global Holdings Inc. grew its holdings in Fresenius Medical Care by 60.4% in the third quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company’s stock valued at $1,340,000 after purchasing an additional 23,692 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Fresenius Medical Care during the 3rd quarter worth $420,000. Institutional investors and hedge funds own 8.37% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on FMS shares. Berenberg Bank began coverage on Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price objective for the company. Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Truist Financial lifted their price target on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a research report on Monday, January 6th. Finally, StockNews.com assumed coverage on Fresenius Medical Care in a research report on Friday, January 3rd. They issued a “strong-buy” rating for the company.

Fresenius Medical Care Stock Down 0.7 %

FMS stock traded down $0.15 during midday trading on Monday, hitting $22.34. 293,111 shares of the company’s stock were exchanged, compared to its average volume of 211,316. The firm has a 50 day moving average price of $22.50 and a 200-day moving average price of $20.78. Fresenius Medical Care AG has a 12-month low of $17.93 and a 12-month high of $24.31. The stock has a market capitalization of $13.11 billion, a price-to-earnings ratio of 18.46, a price-to-earnings-growth ratio of 0.95 and a beta of 0.92. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.